| Critètes d'éligibilité |
-
Enrollment can occur at any time after disease presentation including at time of disease progression or recurrence; for patients who are to be enrolled on COG therapeutic studies, enrollment on APEC14B1 must occur prior to enrollment onto the therapeutic trial
-
Patients with a known or suspected neoplasm that occurs in the pediatric, adolescent or young adult populations are eligible for enrollment as follows:
-
All cancer cases with an International Classification of Diseases for Oncology (ICD-O) histologic behavior code of two "2" (carcinoma in situ) or three "3" (malignant)
-
All neoplastic lesions of the central nervous system regardless of behavior, i.e., benign, borderline or malignant
-
Other benign/borderline conditions including:
-
Mesoblastic nephroma
-
Teratomas
-
Myeloproliferative diseases including transient myeloproliferative disease
-
Langerhan cell histiocytosis
-
Lymphoproliferative diseases
-
Subjects must be =< 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating National Clinical Trials Network (NCTN) ) therapeutic study, for whom there is a higher upper age limit
-
All patients or their parents or legally authorized representatives must sign a written informed consent; parents will be asked to sign a separate consent for their own biospecimen submission
|
Actif en recrutement
Groupe d'étude en oncologie du Québec